Assignee
INTELLIA THERAPEUTICS INC
US·12 granted patents·61 pending applications·18 citations·filing 2017–2025
Top patents by PatentIndex Score
73 records- 0193US11479767B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2019·Granted Oct 25, 2022·12 cites·27 claims
- 0289US11795460B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·24 claims
- 0388US11673911B2Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·2 cites·22 claims
- 0485US2025059532A1Modified Guide RNAsINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0583US11549107B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2019·Granted Jan 10, 2023·2 cites·21 claims
- 0682US2026015611A1Modified Guide RNAsINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0782US2026022358A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0881US2025207130A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0980US12391722B2Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·23 claims
- 1079US12173284B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·0 cites·31 claims
- 1179US2025346625A1Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1277US11965165B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·21 claims
- 1377US2024018496A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1476US11697806B2Polynucleotides, compositions, and methods for genome editingINTELLIA THERAPEUTICS INC·Filed 2020·Granted Jul 11, 2023·1 cites·26 claims
- 1574US2023076357A1Methods and Compositions for Directed Genome EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1673US12460205B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·18 claims
- 1772US2023295587A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1871US2024301377A1Polynucleotides, Compositions, and Methods for Genome EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1971US2025255940A1Compositions and methods for expressing factor ixINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2071US2024124897A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2170US12480109B2Compositions and methods for kallikrein (KLKB1) gene editingINTELLIA THERAPEUTICS INC·Filed 2025·Granted Nov 25, 2025·0 cites·27 claims
- 2270US2025262302A1Compositions and Methods for Reducing MHC Class I in a CellINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2369US2025276017A1Compositions and Methods for Genomic EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2467US2025276090A1Methods and Compositions for Genetically Modifying a CellINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2566US2023203480A1Lipid nanoparticle formulations for crispr/cas componentsINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2665US2024299583A1Modified Guide RNAs for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2765US2025074866A1Modified amine lipidsINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2865US2024139323A1Compositions and Methods for Genetically Modifying CIITA in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2965US2024002820A1Polynucleotides, Compositions, and Methods for Genome Editing Involving DeaminationINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3064US2026043026A1Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)INTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3164US2024076636A1Polynucleotides, Compositions, and Methods for Genome EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3264US2024016934A1Compositions and Methods for Reducing MHC Class II in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3364US2024150761A1Modified Guide RNAs Comprising an Internal Linker for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3464US2026007772A1Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3563US2020248180A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3663US2026035697A1Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3763US2025268940A1Chimeric antigen receptor compositions and usesINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3862US12214023B2Compositions and methods for expressing factor IXINTELLIA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·0 cites·16 claims
- 3962US2023044994A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4062US2024024478A1Compositions and Methods for Reducing HLA-A in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4162US2025302874A1Cd38 compositions and methods for immunotherapyINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4261US2025025580A1Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor FourINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4359US2024316100A1Engineered t cellsINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4457US2021222173A1Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4557US2022372483A1Modified Guide RNAs for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4656US12077483B2Modified amine lipidsINTELLIA THERAPEUTICS INC·Filed 2019·Granted Sep 3, 2024·0 cites·21 claims
- 4756US2022354967A1Compositions and methods for transgene expression from an albumin locusINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4856US2020270617A1Compositions and methods for transgene expression from an albumin locusINTELLIA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4956US2025269062A1Methods for in vivo editing of a liver geneINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5055US2023035659A1Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INTELLIA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →